Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday.

Several other analysts have also commented on AGIO. ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Royal Bank of Canada initiated coverage on shares of Agios Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price objective for the company. J P Morgan Chase & Co restated a “buy” rating and issued a $76.00 price objective on shares of Agios Pharmaceuticals in a report on Monday, September 18th. SunTrust Banks reiterated a “buy” rating and set a $80.00 target price on shares of Agios Pharmaceuticals in a report on Wednesday, October 4th. Finally, Credit Suisse Group lifted their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a report on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. Agios Pharmaceuticals has an average rating of “Buy” and a consensus price target of $75.70.

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) opened at $52.12 on Friday. Agios Pharmaceuticals has a 1-year low of $39.24 and a 1-year high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The business had revenue of $11.35 million during the quarter, compared to analyst estimates of $10.85 million. During the same period last year, the business posted ($1.63) earnings per share. Agios Pharmaceuticals’s quarterly revenue was up 26.4% compared to the same quarter last year. analysts anticipate that Agios Pharmaceuticals will post -6.59 earnings per share for the current fiscal year.

In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 6,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $66.76, for a total value of $400,560.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $67.23, for a total transaction of $144,275.58. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 162,746 shares of company stock valued at $11,082,396. 5.43% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of AGIO. FMR LLC grew its position in shares of Agios Pharmaceuticals by 14.1% during the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock valued at $371,846,000 after acquiring an additional 895,584 shares during the period. Vanguard Group Inc. grew its position in shares of Agios Pharmaceuticals by 23.8% during the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock valued at $165,401,000 after acquiring an additional 617,379 shares during the period. Capital International Investors grew its position in shares of Agios Pharmaceuticals by 0.3% during the 3rd quarter. Capital International Investors now owns 3,138,131 shares of the biopharmaceutical company’s stock valued at $209,470,000 after acquiring an additional 8,294 shares during the period. BB Biotech AG grew its position in shares of Agios Pharmaceuticals by 1.1% during the 2nd quarter. BB Biotech AG now owns 2,869,528 shares of the biopharmaceutical company’s stock valued at $147,637,000 after acquiring an additional 30,000 shares during the period. Finally, BlackRock Inc. grew its position in shares of Agios Pharmaceuticals by 23.5% during the 2nd quarter. BlackRock Inc. now owns 2,675,380 shares of the biopharmaceutical company’s stock valued at $137,648,000 after acquiring an additional 508,306 shares during the period. 94.38% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/16/agios-pharmaceuticals-agio-rating-lowered-to-strong-sell-at-bidaskclub.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.